Also known as: Attruby
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
BridgeBio Pharma reported long term acoramidis data in transthyretin amyloid cardiomyopathy and submitted a US FDA NDA for BBP-418 in LGMD2I/R9. BBP-418 could become the first approved therapy for the disease if cleared.
BridgeBio Pharma announced positive Phase 3 topline results for infigratinib in children with achondroplasia, meeting primary and key secondary endpoints. The company plans regulatory submissions in the U.S. and Europe in the second half of 2026.
